Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aksjekurs
$0.00244926
Markedsverdi
$51.67K
Endring (1 dag)
5.88%
Endring (1 år)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Inntekter for Nuformix plc (NFX)
Inntekter i Sep 2025 TTM: $-5.28M
Ifølge Nuformix plc sine nyeste økonomiske rapporter er selskapets nåværende resultat $-5.28M. I 2024 hadde selskapet et resultat på $-4.88M, en nedgang sammenlignet med resultatet i 2023, som var $-754.56K. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Nuformix plc fra 2014 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$20.46B -387,521.89%
DK
$4.64B -88,033.93%
US
$5.23B -99,160.13%
US
$2.14B -40,584.12%
BE
$1.61B -30,671.66%
AU